Life Science Today
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs.
Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
The Niche Episode 010 – Roche, Abbvie, I-Mab, BioNTech, Pfizer, PPD & Lupus
Roche earns FDA approval for a combined flu/COVID diagnostic, I-Mab signs with Abbvie for $2 billion, PPD partners to treat lupus, and BioNTech/Pfizer add more COVID candidates while Moderna adds bad press.
Sponsors
www.thescopemethod.com
Story References
https://www.businesswire.com/news/home/20200903005517/en/PPD-Lupus-Therapeutics-Collaborate-Support-Lupus-Clinical
https://www.fiercebiotech.com/biotech/pfizer-biontech-quietly-usher-a-5th-covid-19-jab-into-clinic-analyst
https://www.npr.org/2020/09/04/908305074/bad-optics-or-something-more-moderna-executives-stock-sales-raise-concerns
https://www.roche.com/media/releases/med-cor-2020-09-04.htm
https://www.usnews.com/news/us/articles/2020-09-02/us-nih-awards-nine-companies-129-million-to-scale-up-covid-19-testing
Music by Luke Goodson
www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 009 – Healthcare is Politics
This week, we take a break from our normal news cycle to focus on one big idea; healthcare is politics. But first, a quick update.
Sponsors
www.thescopemethod.com
Story References
https://www.sec.gov/Archives/edgar/data/1620463/000156459020041369/atha-s1.htm
Music by Luke Goodson
www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 008 – J&J, Momenta, White House, FDA, Decentralized Trials
Johnson & Johnson acquires Momenta, the White House and FDA disagree, and the emergence of decentralized clinical trial management.
Sponsors
www.thescopemethod.com
Story References
https://www.momentapharma.com/investors-and-news/press-releases/press-releases-details/2020/Momenta-Enters-Definitive-Agreement-with-Johnson–Johnson/
https://www.hhs.gov/coronavirus/testing/recission-guidances-informal-issuances-premarket-review-lab-tests/index.html
http://www.science37.com/solutions/
Music by Luke Goodson
www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 007 – Samsung Biologics, Moderna (again), Microparticles, and Qiagen
Samsung Biologics builds big, Modern (again), microparticles for timed-release chemotherapy, and Qiagen says ‘no’ to acquisitions.
Sponsors
www.thescopemethod.com
Story References
https://samsungbiologics.com/front/en/mediaCenter/pressReleasesView.do?boardSeq=781&schBoardCtgryCcd=&schString=&schBoardYear=&boardDtm=1597071600000&page=1#
https://investors.modernatx.com/news-releases
https://stm.sciencemag.org/content/12/556/eaaz6606
https://www.fiercebiotech.com/medtech/thermo-fisher-s-12-5b-deal-for-qiagen-flops-as-covid-19-test-demand-lights-new-path-forward
Music by Luke Goodson
www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 006 – Biogen, Denali, US Drugs, and Parasitic Sexual Partners
Biogen and Denali partner for Parkinson’s, the US pushes American-based drug manufacturing, and the secret to Parasitic Sexual Partners uncovered.
Sponsors
www.thescopemethod.com
Story References
https://investors.biogen.com/news-releases/news-release-details/biogen-and-denali-collaborate-lrrk2-program-parkinsons-disease
https://science.sciencemag.org/content/early/2020/07/29/science.aaz9445
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832911/
https://www.whitehouse.gov/presidential-actions/executive-order-ensuring-essential-medicines-medical-countermeasures-critical-inputs-made-united-states/
Music by Luke Goodson
www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 005 – Vaccines Reach Warp Speed, Merck, and Tecartus Approved
We review a few of the big winners from operation warp speed, Merck continues to be quietly successful, and a new CAR T treatment, Tecartus, gets FDA approval.
Sponsors
www.thescopemethod.com
Story References
https://s21.q4cdn.com/488056881/files/doc_financials/2020/q2/Merck-2Q20-Earnings-News-Release.pdf
https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/us-fda-approves-kites-tecartus-the-first-and-only-car-t-treatment-for-relapsed-or-refractory-mantle-cell-lymphoma
https://www.hhs.gov/about/news/index.html
Music by Luke Goodson
www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
Responses